ITW

P30320.A03

Application No.: 10/586,454

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 23 2007 Applicants

: Kozo NINOMIYA et al.

Group Art Unit: Unassigned

ppln. No.

: 10/586,454

Examiner: Unassigned

(U.S. National Stage entry of PCT/JP05/00979)

I.A. Filed

: January 26, 2005

Confirmation No.: 4690

For

: MEDICAMENT FOR THERAPEUTIC TREATMENT OF PAIN

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop <u>Amendment</u>
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, and further to the Information Disclosure Statement filed August 21, 2007, Applicants hereby direct the Examiner's attention to the following documents cited in the Supplementary European Search Report with respect to corresponding European Application EP 05704116:

- (1) Ninomiya, Syuzo: Database HCA AN 141: 420351, 2004, XP-002425725; Abstract of: Effects of ginsenoside Rb1 on hyperalgesia in chronic constipation injury rat models. Ehime Igaku, 2004, Vol. 23, No.2, pp. 142-151,
- (2) WO 2004/050892 A1, June 17, 2004;
- (3) U.S. Patent Application Publication No. 2006/127379 (Kim et al.), published June 15, 2006; Applicants note that this document is a family member of document (2);
- (4) EP 1 295 893 A1, March 26, 2003;

P30320.A03 Application No.: 10/586,454

(5) U.S. Patent Application Publication No. 2003/104079 (Sakanaka et al.), publishedJune 5, 2003; Applicants note that this document is a family member of document(4); and

(6) Seong-Soo Choi et al.: Planta Medica, 2003, Vol. 69, No. 11, pp. 1001-1004.

Copies of the above-listed documents (with exception of the U.S. patent application publications) and the Supplementary European Search Report with respect to EP 05704116 are enclosed together with a completed copy of the PTO-1449 Form listing the above-noted documents. The Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Copies of Nah, Neuropharmacology, 2000, Vol. 39, No. 11, pp. 2180-2184 and Nah, Journal of Ginseng Research, 1999, Vol. 23, No. 1, pp. 38-43, which are also cited in the Supplementary European Search Report, are not submitted herewith inasmuch as these documents were submitted with the IDS filed August 21, 2007.

Further to the U.S. Patent and Trademark Office's decision to partially waive the requirement under 37 C.F.R. §1.98 (a)(2)(i) and (iii), copies of the U.S. patent application publications cited above are not enclosed herewith. However, if copies are needed, the Examiner is respectfully requested to contact the undersigned.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and

P30320.A03 Application No.: 10/586,454

Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted, Kozo NINOMIYA et al.

Bruce H. Bernstein

Reg. No. 29,027 Stephen M. Roylance Reg. No. 31,296

October 23, 2007 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191